Heart drug fails to protect duchenne boys from cardiac decline
NCT ID NCT01648634
First seen Nov 20, 2025 · Last updated May 19, 2026 · Updated 17 times
Summary
This study tested whether nebivolol, a beta-blocker, could prevent heart problems in 51 boys aged 10–15 with Duchenne muscular dystrophy. Participants had healthy hearts at the start and were randomly given either the drug or a placebo. The goal was to see if the drug could stop the heart's main pumping chamber from weakening. The trial found no significant benefit from nebivolol over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Armand Trousseau Hospital
Paris, 75012, France
Conditions
Explore the condition pages connected to this study.